198 related articles for article (PubMed ID: 34196678)
1. Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease.
Mucalo L; Brandow AM; Dasgupta M; Mason SF; Simpson PM; Singh A; Taylor BW; Woods KJ; Yusuf FI; Panepinto JA
Blood Adv; 2021 Jul; 5(13):2717-2724. PubMed ID: 34196678
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature.
Hoogenboom WS; Alamuri TT; McMahon DM; Balanchivadze N; Dabak V; Mitchell WB; Morrone KB; Manwani D; Duong TQ
Blood Rev; 2022 May; 53():100911. PubMed ID: 34838342
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors associated with COVID-19 related severity in sickle cell disease.
Yurtsever N; Nandi V; Ziemba Y; Shi PA
Blood Cells Mol Dis; 2021 Dec; 92():102627. PubMed ID: 34823201
[TBL] [Abstract][Full Text] [Related]
4. Interventions for chronic kidney disease in people with sickle cell disease.
Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
[TBL] [Abstract][Full Text] [Related]
5. Sickle cell disease and COVID-19: Susceptibility and severity.
Sayad B; Karimi M; Rahimi Z
Pediatr Blood Cancer; 2021 Aug; 68(8):e29075. PubMed ID: 34061431
[TBL] [Abstract][Full Text] [Related]
6. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
[TBL] [Abstract][Full Text] [Related]
7. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2017 May; 5(5):CD012389. PubMed ID: 28500860
[TBL] [Abstract][Full Text] [Related]
8. Description of a national, multi-center registry of patients with sickle cell disease and SARS-CoV-2 infection: Data from the Pediatric COVID-19 United States Registry.
Dain AS; Diorio C; Fisher BT; Hankins JS; Witmer CM; Boustany M; Burton M; Ferrolino J; Sadaf S; Ross HS; Maron G;
Pediatr Blood Cancer; 2024 Jun; 71(6):e30909. PubMed ID: 38469996
[TBL] [Abstract][Full Text] [Related]
9. Interventions for chronic kidney disease in people with sickle cell disease.
Roy NB; Carpenter A; Dale-Harris I; Dorée C; Estcourt LJ
Cochrane Database Syst Rev; 2023 Aug; 8(8):CD012380. PubMed ID: 37539955
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Rankine-Mullings AE; Nevitt SJ
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD002202. PubMed ID: 36047926
[TBL] [Abstract][Full Text] [Related]
11. Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection.
Minniti CP; Zaidi AU; Nouraie M; Manwani D; Crouch GD; Crouch AS; Callaghan MU; Carpenter S; Jacobs C; Han J; Simon J; Glassberg J; Gordeuk VR; Klings ES
Blood Adv; 2021 Jan; 5(1):207-215. PubMed ID: 33570644
[TBL] [Abstract][Full Text] [Related]
12. A perspective on the sickle cell disease international COVID-19 registry.
Mucalo L; Brandow AM; Singh A
Best Pract Res Clin Haematol; 2022 Sep; 35(3):101385. PubMed ID: 36494148
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals.
Singh A; Brandow AM; Panepinto JA
Blood Adv; 2021 Apr; 5(7):1915-1921. PubMed ID: 33792626
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical outcomes and healthcare utilization of sickle cell disease patients with COVID-19: A 2.5-year follow-up study.
Feit A; Gordon M; Alamuri TT; Hou W; Mitchell WB; Manwani D; Duong TQ
Eur J Haematol; 2023 Oct; 111(4):636-643. PubMed ID: 37492929
[TBL] [Abstract][Full Text] [Related]
15. Risk and protective factors for severe COVID-19 infection in a cohort of patients with sickle cell disease.
Cai J; Chen-Goodspeed A; Idowu M
J Investig Med; 2022 Jun; 70(5):1243-1246. PubMed ID: 35260481
[TBL] [Abstract][Full Text] [Related]
16. Sickle cell disease and coronavirus disease-2019 (COVID-19) infection: a single-center experience.
Devarashetty SP; Grewal US; Le Blanc K; Walton J; Jones T; Shi R; Master SR; Mansour RP; Ramadas P
Postgrad Med J; 2023 Aug; 99(1175):1008-1012. PubMed ID: 37399057
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 outcomes in sickle cell disease and sickle cell trait.
Christian J; Lanzkron S; Naik RP
Best Pract Res Clin Haematol; 2022 Sep; 35(3):101382. PubMed ID: 36494153
[TBL] [Abstract][Full Text] [Related]
18. Coronavirus Disease among Persons with Sickle Cell Disease, United States, March 20-May 21, 2020.
Panepinto JA; Brandow A; Mucalo L; Yusuf F; Singh A; Taylor B; Woods K; Payne AB; Peacock G; Schieve LA
Emerg Infect Dis; 2020 Oct; 26(10):2473-2476. PubMed ID: 32639228
[TBL] [Abstract][Full Text] [Related]
19. Challenges in the Management of Sickle Cell Disease During SARS-CoV-2 Pandemic.
Alsayegh F; Mousa SA
Clin Appl Thromb Hemost; 2020; 26():1076029620955240. PubMed ID: 32873056
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.
Stallworth JR; Jerrell JM; Tripathi A
Am J Hematol; 2010 Oct; 85(10):795-7. PubMed ID: 20645429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
